ArticleBrain tumor research and treatment2026
Tumor Size-Dependent Clinical Outcomes and Complications After Stereotactic Radiosurgery for Sporadic Vestibular Schwannoma.
Article in Brain tumor research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiosurgery (SRS) is an established treatment for vestibular schwannoma (VS), primarily for tumors smaller than 3 cm in diameter. Its role in larger tumors remains controversial and is generally limited to carefully selected patients. This study evaluated long-term outcomes of primary single-session SRS for VS, stratified by tumor size.
methodsWe retrospectively analyzed 160 patients with unilateral sporadic VS treated with SRS between July 2009 and September 2020. SRS was primarily indicated for tumors <3 cm in maximum diameter, while larger tumors were selectively treated in patients without significant brainstem compression or severe neurological deficits. Patients were stratified by Koos grade: Group A (I), Group B (II-III), and Group C (IV). Median follow-up was 96 months. Primary outcomes included progression-free survival (PFS), hearing preservation, and treatment-related complications.
resultsThe overall tumor control rate was 98.1%. The 10-year PFS rates were 100%, 97.4%, and 96.6% for Groups A, B, and C, respectively, with no significant difference (
conclusionWithin appropriately selected patients, SRS provides excellent tumor control across tumor sizes. However, the risks of trigeminal neuralgia and hydrocephalus requiring shunting increased with tumor size, underscoring the need for individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.